Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Impact · against what's priced in

Amgen's Imdelltra trial results provide a concrete path to blockbuster status and first-line maintenance use, which the market had not yet priced into the current valuation. AstraZeneca also benefits from the validation of Imfinzi as a complementary backbone for aggressive lung cancer, though the impact is more incremental.

AMGN+0.50

Challenges what's priced in

The price assumes